90
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Clinical Evolution and Quality of Life in Clinically Based COPD Chronic Bronchitic and Emphysematous Phenotypes: Results from the 1-Year Follow-Up of the STORICO Italian Observational Study

, ORCID Icon, , , , , , ORCID Icon & show all
Pages 2133-2148 | Published online: 21 Jul 2021

References

  • Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009;135(4):975–982. doi:10.1378/chest.08-2062
  • Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–626. doi:10.1016/S2213-2600(17)30207-2
  • Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–161. doi:10.1164/rccm.201201-0034OC
  • Celli BR, Decramer M, Wedzicha JA, et al. An official American thoracic society/European respiratory society statement: research questions in COPD. Eur Respir Rev. 2015;24(136):159–172. doi:10.1183/16000617.00000315
  • Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–604. doi:10.1164/rccm.200912-1843CC
  • Segal LN, Martinez FJ. Chronic obstructive pulmonary disease subpopulations and phenotyping. J Allergy Clin Immunol. 2018;141(6):1961–1971. doi:10.1016/j.jaci.2018.02.035
  • Lahousse L, Seys LJM, Joos GF, et al. Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease. Eur Respir J. 2017;50(2):1602470. doi:10.1183/13993003.02470-2016
  • Landt E, Çolak Y, Lange P, et al. Chronic Cough in individuals with COPD: a Population-Based Cohort Study. Chest. 2020;157(6):1446–1454. doi:10.1016/j.chest.2019.12.038
  • Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–1192. doi:10.1056/NEJMoa1105482
  • Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410–419. doi:10.1183/13993003.01359-2015
  • Canonica GW, Blasi F, Scichilone N, et al. On behalf of STORICO study group characterization of circadian COPD symptoms by phenotype: methodology of the STORICO observational study. Eur J Intern Med. 2017;43:62–68. doi:10.1016/j.ejim.2017.05.021
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD; 2014. Available from: http://goldcopd.org. Accessed November 2019.
  • Scichilone N, Antonelli Incalzi R, Blasi F, et al.; STORICO study group. Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study. BMC Pulm Med. 2019;19(1):171. doi:10.1186/s12890-019-0935-2
  • Mayo Clinic. Low Hemoglobin count. Available from: https://www.mayoclinic.org/symptoms/low-hemoglobin/basics/definition/sym-20050760. Accessed May, 2021.
  • National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.
  • Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish COPD guidelines (GesEPOC): pharmacological treatment of stable COPD. Arch Bronconeumol. 2012;48(7):247–257. doi:10.1016/j.arbres.2012.04.001
  • Lange P, Halpin DM, O’Donnell DE, MacNee W. Diagnosis, assessment, and phenotyping of COPD: beyond FEV1. Int J Chron Obstruct Pulmon Dis. 2016;11:3–12. doi:10.2147/COPD.S85976
  • Miravitlles M, Worth H, Soler Catalauña JJ, et al. Observational study to characterize 24-hour COPD symptoms and their relationship with patient-reported outcomes; results from the ASSESS study. Respir Res. 2014;15(1):122. doi:10.1186/s12931-014-0122-1
  • Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586. doi:10.1136/thx.54.7.581
  • Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
  • Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure for chronic airflow limitation. The St George’s respiratory questionnaire. Am Rev Respir Dis. 1992;145(6):1321–1327. doi:10.1164/ajrccm/145.6.1321
  • Meguro M, Barley EA, Spencer S, Jones PW. Development and validation of an improved COPD-specific version of the St George’s respiratory questionnaire. Chest. 2007;132(2):456–463. doi:10.1378/chest.06-0702
  • Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi:10.1111/j.1600-0447.1983.tb09716.x
  • Barth J, Martin CR. Factor structure of the hospital anxiety and depression scale (HADS) in German coronary heart disease patients. Health Qual Life Outcomes. 2005;3(1):15. doi:10.1186/1477-7525-3-15
  • Pokrzywinski RF, Meads DM, McKenna SP, Glendenning GA, Revicki DA. Development and psychometric assessment of the COPD and Asthma Sleep Impact Scale (CASIS). Health Qual Life Outcomes. 2009;7(1):98. doi:10.1186/1477-7525-7-98
  • Ainsworth BE, Bassett DR Jr, Strath SJ, et al. Comparison of three methods for measuring the time spent in physical activity. Med Sci Sports Exerc. 2000;32(9 Suppl):S457–64. doi:10.1097/00005768-200009001-00004
  • Puhan MA, Frey M, Büchi S, Schünemann HJ. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2008;6(1):46. doi:10.1186/1477-7525-6-46
  • Andreas S, Röver C, Heinz J, Straube S, Watz H, Friede T. Decline of COPD exacerbations in clinical trials over two decades - a systematic review and meta-regression. Respir Res. 2019;20(1):186. doi:10.1186/s12931-019-1163-2
  • Hernández Vázquez J, Ali García I, Jiménez-García R, et al. COPD phenotypes: differences in survival. Int J Chron Obstruct Pulmon Dis. 2018;20(13):2245–2251. doi:10.2147/COPD.S166163
  • Calle Rubio M, Casamor R, Miravitlles M. Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study. Int J Chron Obstruct Pulmon Dis. 2017;12:2373–2383. doi:10.2147/COPD.S137872
  • Bettoncelli G, Blasi F, Brusasco V, et al. The clinical and integrated management of COPD. An official document of AIMAR (Interdisciplinary Association for Research in Lung Disease), AIPO (Italian Association of Hospital Pulmonologists), SIMER (Italian Society of Respiratory Medicine), SIMG (Italian Society of General Medicine). Multidiscip Respir Med. 2014;9(1):25. doi:10.1186/2049-6958-9-25
  • Wilke S, Spruit MA, Wouters EF, Schols JM, Franssen FM, Janssen DJ. Determinants of 1-year changes in disease-specific health status in patients with advanced chronic obstructive pulmonary disease: a 1-year observational study. Int J Nurs Pract. 2015;21(3):239–248. doi:10.1111/ijn.12265.
  • Cosio BG, Soriano JB, López-Campos JL, et al. CHAIN study. distribution and outcomes of a phenotype-based approach to guide COPD management: results from the CHAIN Cohort. PLoS One. 2016;11(9):e0160770. doi:10.1371/journal.pone.0160770